The Latest Cardiac and Vascular News
New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039 WARRINGTON, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the United […]
GENT, Belgium–(BUSINESS WIRE)–Today, FEops announced the publication of the PREDICT-LAA study in JACC: Cardiovascular Interventions, showing that Left Atrial Appendage Closure (LAAC) procedures planned by means of FEops HEARTguide™ resulted in significant improvement of procedural efficiency and outcomes. Prof. Dr. Ole De Backer (Copenhagen, Denmark), Principal Investigator of this study, […]
Enterprise-grade digital stethoscope platform brings non-invasive heart disease detection to primary care OAKLAND, Calif., Feb. 23, 2023 /PRNewswire/ — Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI that objectively identifies structural […]
ANDOVER, Mass., Feb. 23, 2023 /PRNewswire/ — Transmural Systems the leader in transcatheter electrosurgery for structural interventions announced today successful first-in-human procedure with its TELLTALE electrosurgical guidewire system. The TELLTALE Guidewire System is the first and only dedicated electrosurgical solution to simplify the BASILICA-TAVR procedure for transcatheter traversal and laceration of native […]
ANDOVER, Mass., Feb. 22, 2023 /PRNewswire/ – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2022. Recent Highlights Total revenue of $31.4 million in the fourth quarter […]
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial hypertension (PAH) PH-ILD shares clinical and pathophysiological features with PAH, however, there is only one currently approved therapy in PH-ILD and unmet need remains high […]
WARRINGTON, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the Company’s Board of Directors has approved a 1-for-50 reverse stock split of its issued and outstanding common […]
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE) Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment […]
Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for the Healthcare Providers Design Patent Complements Existing U.S. and European Design Patents as Feedback During Recent Meetings Continues to Support a Positive User Experience HINGHAM, Mass., Feb. 23, 2023 (GLOBE […]
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 trial of low-dose infigratinib as a potential treatment option for children with achondroplasia continues to progress […]
